Lyell Immunopharma (LYEL) Preferred Stock Liabilities (2020 - 2021)

Lyell Immunopharma has reported Preferred Stock Liabilities for 2 years, with the latest figure at $1.0 billion in Q1 2021.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.0 billion in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $1.0 billion (changed N/A YoY) and the FY2020 annual result came in at $1.0 billion, up 94.73% from the prior year.
• Preferred Stock Liabilities steadied at $1.0 billion in Q1 2021 per LYEL's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $1.0 billion in Q2 2020 and troughed at $1.0 billion in Q2 2020.